Trial Outcomes & Findings for Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study (NCT NCT03872427)
NCT ID: NCT03872427
Last Updated: 2025-11-14
Results Overview
Best overall response rate (BORR) based on RECIST V1.1 achieved by 6 months of CB-839 HCl treatment
Recruitment status
ACTIVE_NOT_RECRUITING
Study phase
PHASE2
Target enrollment
54 participants
Primary outcome timeframe
Up to 6 months from treatment start date
Results posted on
2025-11-14
Participant Flow
Out of the 55 patients enrolled, one patient did not receive treatment due to a death before starting the trial.
Participant milestones
| Measure |
Cohort 1
NF1 mutant malignant peripheral nerve sheath tumors (MPNST)
|
Cohort 2
NF1 mutant other cancers
|
Cohort 3
KEAP1/NRF2 mutant cancers
|
Cohort 4
STK11/LKB1 mutant cancers
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
9
|
26
|
9
|
10
|
|
Overall Study
COMPLETED
|
9
|
26
|
9
|
10
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
Baseline characteristics by cohort
| Measure |
Cohort 1
n=9 Participants
NF1 mutant malignant peripheral nerve sheath tumors (MPNST)
|
Cohort 2
n=26 Participants
NF1 mutant other cancers
|
Cohort 3
n=9 Participants
KEAP1/NRF2 mutant cancers
|
Cohort 4
n=10 Participants
STK11/LKB1 mutant cancers
|
Total
n=54 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=10 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=45 Participants
|
0 Participants
n=44 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
7 Participants
n=10 Participants
|
12 Participants
n=10 Participants
|
7 Participants
n=20 Participants
|
8 Participants
n=45 Participants
|
34 Participants
n=44 Participants
|
|
Age, Categorical
>=65 years
|
2 Participants
n=10 Participants
|
14 Participants
n=10 Participants
|
2 Participants
n=20 Participants
|
2 Participants
n=45 Participants
|
20 Participants
n=44 Participants
|
|
Sex: Female, Male
Female
|
4 Participants
n=10 Participants
|
17 Participants
n=10 Participants
|
4 Participants
n=20 Participants
|
5 Participants
n=45 Participants
|
30 Participants
n=44 Participants
|
|
Sex: Female, Male
Male
|
5 Participants
n=10 Participants
|
9 Participants
n=10 Participants
|
5 Participants
n=20 Participants
|
5 Participants
n=45 Participants
|
24 Participants
n=44 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=10 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=20 Participants
|
1 Participants
n=45 Participants
|
2 Participants
n=44 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
8 Participants
n=10 Participants
|
26 Participants
n=10 Participants
|
9 Participants
n=20 Participants
|
9 Participants
n=45 Participants
|
52 Participants
n=44 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=10 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=45 Participants
|
0 Participants
n=44 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=10 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=45 Participants
|
0 Participants
n=44 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=10 Participants
|
0 Participants
n=10 Participants
|
1 Participants
n=20 Participants
|
1 Participants
n=45 Participants
|
2 Participants
n=44 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=10 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=45 Participants
|
0 Participants
n=44 Participants
|
|
Race (NIH/OMB)
Black or African American
|
5 Participants
n=10 Participants
|
2 Participants
n=10 Participants
|
1 Participants
n=20 Participants
|
1 Participants
n=45 Participants
|
9 Participants
n=44 Participants
|
|
Race (NIH/OMB)
White
|
4 Participants
n=10 Participants
|
24 Participants
n=10 Participants
|
7 Participants
n=20 Participants
|
7 Participants
n=45 Participants
|
42 Participants
n=44 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=10 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=45 Participants
|
0 Participants
n=44 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=10 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=20 Participants
|
1 Participants
n=45 Participants
|
1 Participants
n=44 Participants
|
|
Region of Enrollment
United States
|
9 participants
n=10 Participants
|
26 participants
n=10 Participants
|
9 participants
n=20 Participants
|
10 participants
n=45 Participants
|
54 participants
n=44 Participants
|
PRIMARY outcome
Timeframe: Up to 6 months from treatment start dateBest overall response rate (BORR) based on RECIST V1.1 achieved by 6 months of CB-839 HCl treatment
Outcome measures
| Measure |
Cohort 4
n=10 Participants
STK11/LKB1 mutant cancers
|
Cohort 1
n=9 Participants
NF1 mutant malignant peripheral nerve sheath tumors (MPNST)
|
Cohort 2
n=26 Participants
NF1 mutant other cancers
|
Cohort 3
n=9 Participants
KEAP1/NRF2 mutant cancers
|
|---|---|---|---|---|
|
Best Overall Response Rate by 6 Months
Progressive disease (PD)
|
5 Participants
|
4 Participants
|
14 Participants
|
6 Participants
|
|
Best Overall Response Rate by 6 Months
Treatment Failure
|
1 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
|
Best Overall Response Rate by 6 Months
Stable Disease (SD)
|
4 Participants
|
4 Participants
|
10 Participants
|
2 Participants
|
|
Best Overall Response Rate by 6 Months
Complete Response (CR)/Partial response (PR)
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Up to 2 years from treatment start dateWill be assessed by Common Terminology Criteria for Adverse Events version 5.0. Will tabulate toxicity by cohort, type, severity and attribution.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Time to progression or death whichever comes first, assessed up to 2 years from treatment start dateWill estimate using the Kaplan-Meier method with time zero set to cycle 1, day 1 (C1D1). Will estimate the medians and select probabilities along with 95% confidence intervals. If more than a handful of patients die without progression, will use Aalen-Johansen estimates to adjust for the competing risk of death.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Time to progression starting at C1D1, assessed up to 2 years from treatment start dateWill estimate the medians and select probabilities along with 95% confidence intervals. If more than a handful of patients die without progression, will use Aalen-Johansen estimates to adjust for the competing risk of death.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Time to death from any cause, assessed up to 2 years from treatment start dateWill estimate using the Kaplan-Meier method with time zero set to C1D1. Will estimate the medians and select probabilities along with 95% confidence intervals. If more than a handful of patients die without progression, will use Aalen-Johansen estimates to adjust for the competing risk of death.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: From start of treatment until disease progression/recurrence, assessed up to 2 yearsOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Up to 2 years from treatment start dateOutcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline up to between 0-8 hours post-glutaminase inhibitor CB-839 hydrochloride doseWill assess PD changes before and after treatment using the Wilcoxon signed rank test. Will correlate these changes with response to treatment using Wilcoxon rank sum test. Will also perform a receiver operating characteristic curve analysis.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline up to between 0-8 hours post-glutaminase inhibitor CB-839 hydrochloride doseWill assess PD changes before and after treatment using the Wilcoxon signed rank test. Will correlate these changes with response to treatment using Wilcoxon rank sum test. Will also perform a receiver operating characteristic curve analysis.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline up to between 0-8 hours post-glutaminase inhibitor CB-839 hydrochloride doseWill assess PD changes before and after treatment using the Wilcoxon signed rank test. Will correlate these changes with response to treatment using Wilcoxon rank sum test. Will also perform a receiver operating characteristic curve analysis.
Outcome measures
Outcome data not reported
Adverse Events
Cohort 1
Serious events: 5 serious events
Other events: 9 other events
Deaths: 7 deaths
Cohort 2
Serious events: 7 serious events
Other events: 24 other events
Deaths: 20 deaths
Cohort 3
Serious events: 4 serious events
Other events: 8 other events
Deaths: 6 deaths
Cohort 4
Serious events: 6 serious events
Other events: 10 other events
Deaths: 8 deaths
Serious adverse events
| Measure |
Cohort 1
n=9 participants at risk
NF1 mutant malignant peripheral nerve sheath tumors (MPNST)
|
Cohort 2
n=26 participants at risk
NF1 mutant other cancers
|
Cohort 3
n=9 participants at risk
KEAP1/NRF2 mutant cancers
|
Cohort 4
n=10 participants at risk
STK11/LKB1 mutant cancers
|
|---|---|---|---|---|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Injury, poisoning and procedural complications
Acute kidney injury
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Appendicitis
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Blood and lymphatic system disorders
Bacteremia
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Blood and lymphatic system disorders
Blood bilirubin increased
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Cardiac disorders
Chest wall pain
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Colonic obstruction
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
22.2%
2/9 • 4 years
|
20.0%
2/10 • 4 years
|
|
General disorders
Death NOS
|
11.1%
1/9 • 4 years
|
7.7%
2/26 • 4 years
|
0.00%
0/9 • 4 years
|
20.0%
2/10 • 4 years
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
11.1%
1/9 • 4 years
|
20.0%
2/10 • 4 years
|
|
Nervous system disorders
Encephalopathy
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Esophageal obstruction
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
General disorders
Fever
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Musculoskeletal and connective tissue disorders
Gait disturbance
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
General disorders
General and admin site - Other - Failure To Thrive
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
General disorders
Generalized edema
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
General disorders
Generalized muscle weakness
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Blood and lymphatic system disorders
Hypercalcemia
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Blood and lymphatic system disorders
Hyponatremia
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Hypoxia
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Infections and infestations
Lung infection
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Nausea
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Nervous system disorders
Nervous system - Other - L5 Lumbar Lesion Compress Nerve Route
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Non-cardiac chest pain
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Pain
|
0.00%
0/9 • 4 years
|
7.7%
2/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Respiratory, thoracic and mediastinal disorders
Resp, thoracic & mediast - Other - Hemoptysis
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Tracheal obstruction
|
22.2%
2/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Tumor pain
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Vomiting
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
Other adverse events
| Measure |
Cohort 1
n=9 participants at risk
NF1 mutant malignant peripheral nerve sheath tumors (MPNST)
|
Cohort 2
n=26 participants at risk
NF1 mutant other cancers
|
Cohort 3
n=9 participants at risk
KEAP1/NRF2 mutant cancers
|
Cohort 4
n=10 participants at risk
STK11/LKB1 mutant cancers
|
|---|---|---|---|---|
|
Infections and infestations
Infections & infestations - Other - Covid
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Infections and infestations
Infections & infestations - Other - Covid-19
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Injury, poisoning and procedural complications
Injury/poison/procedure - Other - Dislocation Of Rib (Left)
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Psychiatric disorders
Insomnia
|
22.2%
2/9 • 4 years
|
7.7%
2/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Reproductive system and breast disorders
Irregular menstruation
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Investigations
Lymphocyte count decreased
|
44.4%
4/9 • 4 years
|
38.5%
10/26 • 4 years
|
22.2%
2/9 • 4 years
|
30.0%
3/10 • 4 years
|
|
Nervous system disorders
Memory impairment
|
11.1%
1/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Metabolism and nutrition disorders
Metabolism and nutrition - Other - Positive For Appetite Change
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Musculoskeletal and connective tissue disorders
Muscle cramp
|
11.1%
1/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Musculoskeletal and connective tissue disorders
Musculoskel/connect tissue -Other - Right Hip Pain
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Musculoskeletal and connective tissue disorders
Musculoskel/connect tissue -Other - Shaking At Night
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Musculoskeletal and connective tissue disorders
Musculoskel/connect tissue -Other - Tumor Pain (Back)
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Nausea
|
33.3%
3/9 • 4 years
|
34.6%
9/26 • 4 years
|
11.1%
1/9 • 4 years
|
30.0%
3/10 • 4 years
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
11.1%
1/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Investigations
Neutrophil count decreased
|
22.2%
2/9 • 4 years
|
19.2%
5/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Non-cardiac chest pain
|
11.1%
1/9 • 4 years
|
7.7%
2/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
General disorders
Pain
|
22.2%
2/9 • 4 years
|
7.7%
2/26 • 4 years
|
11.1%
1/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Nervous system disorders
Peripheral motor neuropathy
|
11.1%
1/9 • 4 years
|
7.7%
2/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Reproductive system and breast disorders
Reproductive and breast - Other - Abnormal Image Finding
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Reproductive system and breast disorders
Reproductive and breast - Other - Sclerosing Intraductal Papilloma Without Atypia
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Skin and subcutaneous tissue disorders
Skin & subcutaneous tissue -Other - Cellulitis
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Skin and subcutaneous tissue disorders
Skin & subcutaneous tissue -Other - Joint Swelling
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Skin and subcutaneous tissue disorders
Skin & subcutaneous tissue -Other - Skin Infection (Cut/Right Foot Wound)
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Skin and subcutaneous tissue disorders
Skin papilloma
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Musculoskeletal and connective tissue disorders
Trismus
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Tumor pain
|
11.1%
1/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Voice alteration
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Vomiting
|
22.2%
2/9 • 4 years
|
23.1%
6/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Metabolism and nutrition disorders
Weight gain
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Metabolism and nutrition disorders
Weight loss
|
22.2%
2/9 • 4 years
|
15.4%
4/26 • 4 years
|
33.3%
3/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Investigations
White blood cell decreased
|
22.2%
2/9 • 4 years
|
19.2%
5/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Investigations
AST increased
|
0.00%
0/9 • 4 years
|
30.8%
8/26 • 4 years
|
11.1%
1/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Investigations
Activated PTT prolonged
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Allergic reaction
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Blood and lymphatic system disorders
Bacteremia
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Blood and lymphatic system disorders
Blood bilirubin increased
|
0.00%
0/9 • 4 years
|
11.5%
3/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Blood and lymphatic system disorders
Blood/Lymph - Other - Neutropenia
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Infections and infestations
Bronchial infection
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Cholecystitis
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Psychiatric disorders
Depression
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Eye disorders
Dry eye
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
11.1%
1/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Ear and labyrinth disorders
Ear and Labyrinth - Other - Hyperacusis
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Edema limbs
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Investigations
Elevated LDH
|
0.00%
0/9 • 4 years
|
15.4%
4/26 • 4 years
|
22.2%
2/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Eye disorders
Eye disorders - Other, specify - Visual Disturbance
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Eye disorders
Floaters
|
0.00%
0/9 • 4 years
|
7.7%
2/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
GI disorders - Other, specify - Heartburn
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Gastroesophageal reflux disease
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Musculoskeletal and connective tissue disorders
Generalized muscle weakness
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Hiccups
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Metabolism and nutrition disorders
Hypocalcemia
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Metabolism and nutrition disorders
Hypokalemia
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Metabolism and nutrition disorders
Hypomagnesemia
|
0.00%
0/9 • 4 years
|
7.7%
2/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Vascular disorders
Hypotension
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Infections and infestations
Infections & infestations - Other - Covid19 Positive
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Investigations
Lipase increased
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Malaise
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Metabolism and nutrition disorders
Metabolism and nutrition - Other - Lactic Acidosis
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Metabolism and nutrition disorders
Metabolism and nutrition - Other - Metabolic Acidosis
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Mucositis oral
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Nervous system disorders
Nervous system - Other - Numbness To Bilateral Foot R>L
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Oral dysesthesia
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Pain in extremity
|
0.00%
0/9 • 4 years
|
7.7%
2/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Nervous system disorders
Paresthesia
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Periorbital edema
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Nervous system disorders
Photophobia
|
0.00%
0/9 • 4 years
|
23.1%
6/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Investigations
Platelet count decreased
|
0.00%
0/9 • 4 years
|
19.2%
5/26 • 4 years
|
22.2%
2/9 • 4 years
|
20.0%
2/10 • 4 years
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhea
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Investigations
Serum amylase increased
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Infections and infestations
Shingles
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Skin and subcutaneous tissue disorders
Skin & subcutaneous tissue -Other - Itching
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Stomach pain
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Tremor
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Renal and urinary disorders
Urinary frequency
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Nervous system disorders
Confusion
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Investigations
INR increased
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Musculoskeletal and connective tissue disorders
Muscle weakness lower limb
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Rectal pain
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Renal and urinary disorders
Renal & urinary disorders - Other - Difficulty Urination
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
11.1%
1/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
General disorders
Adrenal insufficiency
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Nervous system disorders
Delirium
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
General disorders
Hoarseness
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
General disorders
Hypoxia
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Investigations
Investigations - Other, specify - Ldh Increase
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
General disorders
Localized edema
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Skin and subcutaneous tissue disorders
Rash acneiform
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Respiratory, thoracic and mediastinal disorders
Resp, thoracic & mediast - Other - Hypoxemia
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Respiratory, thoracic and mediastinal disorders
Resp, thoracic & mediast - Other - Pulmonary Opacities
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
General disorders
Seroma
|
0.00%
0/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Infections and infestations
Bladder infection
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Bruising
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Cardiac disorders
Chest wall pain
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Chills
|
11.1%
1/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Investigations
Cholesterol high
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Nervous system disorders
Concentration impairment
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Constipation
|
22.2%
2/9 • 4 years
|
23.1%
6/26 • 4 years
|
22.2%
2/9 • 4 years
|
20.0%
2/10 • 4 years
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
33.3%
3/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Investigations
Creatinine increased
|
11.1%
1/9 • 4 years
|
15.4%
4/26 • 4 years
|
11.1%
1/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Metabolism and nutrition disorders
Dehydration
|
11.1%
1/9 • 4 years
|
7.7%
2/26 • 4 years
|
0.00%
0/9 • 4 years
|
20.0%
2/10 • 4 years
|
|
Gastrointestinal disorders
Diarrhea
|
11.1%
1/9 • 4 years
|
7.7%
2/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Nervous system disorders
Dizziness
|
11.1%
1/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Dysgeusia
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Dysphagia
|
11.1%
1/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
33.3%
3/9 • 4 years
|
7.7%
2/26 • 4 years
|
11.1%
1/9 • 4 years
|
30.0%
3/10 • 4 years
|
|
Ear and labyrinth disorders
Ear and Labyrinth - Other - Decreased Hearing
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Edema face
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Eye disorders
Eye disorders - Other, specify - Sty
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
Fall
|
22.2%
2/9 • 4 years
|
3.8%
1/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
General disorders
Fatigue
|
55.6%
5/9 • 4 years
|
34.6%
9/26 • 4 years
|
11.1%
1/9 • 4 years
|
30.0%
3/10 • 4 years
|
|
General disorders
Fever
|
11.1%
1/9 • 4 years
|
7.7%
2/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
General and admin site - Other - Migraine
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
General disorders
General and admin site - Other - Sleep Disorder
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Nervous system disorders
Headache
|
22.2%
2/9 • 4 years
|
11.5%
3/26 • 4 years
|
11.1%
1/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Metabolism and nutrition disorders
Hypercalcemia
|
11.1%
1/9 • 4 years
|
19.2%
5/26 • 4 years
|
33.3%
3/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
11.1%
1/9 • 4 years
|
7.7%
2/26 • 4 years
|
11.1%
1/9 • 4 years
|
20.0%
2/10 • 4 years
|
|
Metabolism and nutrition disorders
Hyperkalemia
|
22.2%
2/9 • 4 years
|
7.7%
2/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Vascular disorders
Hypertension
|
11.1%
1/9 • 4 years
|
7.7%
2/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Metabolism and nutrition disorders
Hypoalbuminemia
|
11.1%
1/9 • 4 years
|
3.8%
1/26 • 4 years
|
22.2%
2/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
11.1%
1/9 • 4 years
|
0.00%
0/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Metabolism and nutrition disorders
Hyponatremia
|
55.6%
5/9 • 4 years
|
26.9%
7/26 • 4 years
|
44.4%
4/9 • 4 years
|
40.0%
4/10 • 4 years
|
|
Metabolism and nutrition disorders
Hypophosphatemia
|
22.2%
2/9 • 4 years
|
3.8%
1/26 • 4 years
|
22.2%
2/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Metabolism and nutrition disorders
Anorexia
|
22.2%
2/9 • 4 years
|
19.2%
5/26 • 4 years
|
33.3%
3/9 • 4 years
|
30.0%
3/10 • 4 years
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
11.1%
1/9 • 4 years
|
7.7%
2/26 • 4 years
|
0.00%
0/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
11.1%
1/9 • 4 years
|
7.7%
2/26 • 4 years
|
0.00%
0/9 • 4 years
|
20.0%
2/10 • 4 years
|
|
Investigations
ALT increased
|
22.2%
2/9 • 4 years
|
42.3%
11/26 • 4 years
|
11.1%
1/9 • 4 years
|
0.00%
0/10 • 4 years
|
|
Gastrointestinal disorders
Abdominal pain
|
11.1%
1/9 • 4 years
|
23.1%
6/26 • 4 years
|
11.1%
1/9 • 4 years
|
20.0%
2/10 • 4 years
|
|
Investigations
Alkaline phosphatase increased
|
11.1%
1/9 • 4 years
|
30.8%
8/26 • 4 years
|
0.00%
0/9 • 4 years
|
10.0%
1/10 • 4 years
|
|
Blood and lymphatic system disorders
Anemia
|
22.2%
2/9 • 4 years
|
38.5%
10/26 • 4 years
|
55.6%
5/9 • 4 years
|
30.0%
3/10 • 4 years
|
Additional Information
Dr. Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Phone: (713) 794-1226
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: LTE60